Valuation Arithmetic

At $12.18 the equity is worth $1.26 billion against $1.59 billion of net debt, so the market carries the enterprise at $2.86 billion — 4.3 times trailing adjusted EBITDA — and the shares are 44% of that. One turn of the multiple is $6.46 a share. The return available from here is mostly debt repayment moving across to the equity, and the four years to 2025 already ran that experiment.

Between 2021 and 2025 Herbalife generated $1,143.8 million of free cash flow and cut Credit Agreement total debt from $2,845.8 million to $2,050.0 million, and over the same four years its equity fell from $4,433 million to $1,335 million, because adjusted EBITDA dropped 24.7% and the enterprise multiple went from 7.6 times to 4.6 times. [1] [2]

The same experiment already ran, from 2021 to 2025

Cumulative free cash flow across those four years was $1,143.8 million — $308.9 million, $196.1 million, $222.5 million, $163.4 million and $252.9 million [3] [4] — and Credit Agreement total debt came down $795.8 million, from $2,845.8 million to $2,050.0 million [5]. Over the same period the equity went from $4,433 million to $1,335 million, a fall of $3,098 million, or 2.5 times Herbalife's entire market value today.

The other two terms are where it went. Adjusted EBITDA fell 24.7%, from $873.5 million to $657.6 million, and the enterprise multiple went from 7.6 times to 4.6 times [6]. Enterprise value fell $3.6 billion while debt came down $0.8 billion, and the difference landed entirely on the residual claim. That is the strongest fact against the deleveraging case, and it is the record of the period that produced today's balance sheet.

The forward version of the same trade is the smaller one. The stated target takes gross debt to $1.4 billion by 2028 and net debt from $1,593.4 million to below $1.0 billion [7]. That is $593 million: $5.72 a share flat across every cell of the sensitivity grid below, and $17.90 a share at an unchanged multiple. The transfer that already ran was the larger one on the debt side, $795.8 million retired, and it came alongside $3,098 million of equity value lost.

Two of the starting conditions have changed, and they are the two that did the damage. Adjusted EBITDA has risen for two consecutive years — $570.6 million in 2023, $634.8 million in 2024, $657.6 million in 2025, with 2026 guided to $675 million to $705 million [8] — rather than falling, and the multiple starts at 4.3 times against 7.6 times, so there is 44% less of it to lose.

The cash-flow half of the record carries its own qualification, and it runs against the bull case. Cash capital expenditure fell from $151.4 million in 2021 to $80.4 million in 2025 [9] [10], and between 2023 and 2025 free cash flow rose $30.4 million while operating cash flow fell $24.2 million. The improvement came from the capital line rather than from operations, and the company guides 2026 capital expenditure to $50 million to $80 million with a further $35 million to $55 million of capitalised software implementation cost on top of it [11] — $85 million to $135 million combined against $80.4 million spent in 2025. The capital line cannot make that contribution again.

The enterprise, and the slice of it that is equity

Herbalife had 103,669,416 common shares outstanding on 29 April 2026 [12]. At the 27 July 2026 close of $12.18 that is $1,262.7 million of market value. Against it sit $2,044.6 million of Credit Agreement total debt and $451.2 million of cash at 31 March 2026, which the company nets to $1,593.4 million [13]. Enterprise value is therefore about $2,856 million.

Sources: share count of 103,669,416 per the Q1 2026 Form 10-Q cover [14]; debt, cash and trailing adjusted EBITDA of $668.4 million per the May 2026 earnings presentation [15]; closing price 27 July 2026 as reported.

The choice of denominator changes the answer by nearly a turn. Trailing twelve months to March 2026, Herbalife reports unadjusted EBITDA of $617.7 million, adjusted EBITDA of $668.4 million and Credit Agreement EBITDA of $744.0 million [16]. The same enterprise value is 4.6 times, 4.3 times and 3.8 times those three figures. The comparisons below use the unadjusted measure against peers, because that is what the peer data supports, and the adjusted measure where Herbalife's own guidance is the reference.

Equity is 44.2% of enterprise value, so the enterprise is levered 2.26 times into the shares: a 10% move in enterprise value is a 23% move in the equity. That is the leverage described in Business and Balance Sheet, stated as a coefficient.

The multiple, in its own history

Source: derived from year-end closing prices and share counts as reported, with Credit Agreement total debt and cash per the June 2026 corporate overview [17] and the May 2026 earnings presentation [18].

Sources: adjusted EBITDA 2021–2025 and Credit Agreement total debt per the June 2026 corporate overview [19]; trailing adjusted EBITDA of $668.4 million and net debt of $1,593.4 million per the May 2026 earnings presentation [20]; enterprise value derived from reported prices and share counts.

Adjusted EBITDA fell from $873.5 million in 2021 to $570.6 million in 2023 and recovered to $657.6 million in 2025 [21]. The multiple on it fell further and has not recovered: 7.6 times at the end of 2021, 4.3 times today. The equity's share of enterprise value went to 26% at the end of 2024, when the shares closed the year at $6.69, and is back to 44% now.

The peer set has been repriced with it

Source: derived from each company's reported financial statements (operating income plus depreciation and amortisation for the last completed fiscal year, with the most recent quarterly balance sheet) and closing prices on 27 July 2026; Herbalife's EBITDA of $602.7 million for 2025 per the June 2026 corporate overview [22]. Fiscal year-ends differ, as shown.

The peer set is the one Herbalife names in its own Item 1 and that Channel or Category used to separate a product problem from a distribution problem. On the growth evidence that chapter assembled, the retail branded-protein names were the winners: BellRing grew net sales 16% to $2,316.6 million in the year to September 2025 [23], and Simply Good Foods grew 9.0% to $1,450.9 million in the year to August 2025 [24].

The market has not paid for that growth. Since 31 December 2024 BellRing has fallen 83% and Simply Good Foods 73%, while Herbalife has risen 82%. Both retail names now trade near seven times their last reported full-year EBITDA, and both have since reported lower operating profit than the prior-year period. Herbalife at 4.7 times sits between them and the two lowest-rated direct sellers — Nu Skin at 2.4 times on revenue down 14.3%, and USANA at 3.6 times on revenue up 8.3%. Medifast's enterprise value is negative: its $109 million of market value is below the $169 million of cash on its balance sheet.

The useful conclusion is narrower than "Herbalife is cheap against faster-growing peers". The whole complex has been marked down, and against it Herbalife sits 2.4 turns below BellRing and 2.4 turns above Nu Skin. What the multiple is not doing is discriminating on growth: Nature's Sunshine, growing 5.7%, carries the highest multiple in the table at 7.3 times, and it is a $282 million enterprise.

What debt repayment is worth to the shares

The company's stated capital priority is explicit. Asked on the May 2026 call whether the completed refinancing changed anything, the CFO said the number one priority remained reducing gross debt to $1.4 billion by 2028, "which would get our net debt below $1 billion" [25]. That is a $593 million reduction from the $1,593.4 million reported at March 2026 [26], spread over the eleven quarters to the end of 2028 — about $54 million a quarter.

Herbalife generated $333.3 million of operating cash flow against $80.4 million of capital expenditure in 2025, or $252.9 million of free cash flow, and paid $205.7 million of cash interest [27]. That is $63 million a quarter — enough for the target, with nothing left over. The April refinancing adds roughly $45 million of annualised cash interest saving, against a $20 million to $25 million full-year headwind from the India goods-and-services-tax mismatch [28].

Two pieces of arithmetic follow. First, $252.9 million of 2025 free cash flow against $1,262.7 million of market value is a 20.0% free-cash-flow yield; on a normalised figure of roughly $275 million after the interest saving and the India cost, 21.8%. Second, if the enterprise value stays where it is and net debt falls to $1.0 billion, the residual left to the equity is $1,856 million, or $17.90 a share — 47% above today's price, without any change in the multiple and without growth. The consensus target price of $18.33 is essentially that same calculation, drawn from a coverage list of two to three contributing analysts.

Sources: adjusted EBITDA per the June 2026 corporate overview [29]; free cash flow derived as operating cash flow less purchases of property, plant and equipment per the FY2025 Form 10-K statements of cash flows [30] and the equivalent prior-year statements.

Conversion of adjusted EBITDA into free cash flow has run between 25.7% and 39.0% over five years and averaged 33.4%, with no trend. Cash interest is most of the gap: $205.7 million in 2025 was 31% of adjusted EBITDA [31]. A 20% free-cash-flow yield on this equity is the arithmetic consequence of a business converting a third of its EBITDA to cash while carrying 56% of its enterprise value in debt.

Sensitivity

Source: derived from reported figures — equity value per share equals the multiple times adjusted EBITDA less $1,593.4 million of net debt [32], divided by 103,669,416 shares [33]. Columns are adjusted EBITDA levels: $570M is the 2023 trough, $670M approximates the trailing figure, $720M is above the top of 2026 guidance.

The grid holds net debt at today's $1,593.4 million. Reaching the stated end-2028 target of $1.0 billion adds a flat $5.72 to every cell — the $593 million of repayment divided by the share count.

Two readings come out of it. The case is most sensitive to the multiple: one turn on trailing adjusted EBITDA is $6.46 a share, 53% of the current price, while a $50 million move in adjusted EBITDA at today's multiple is $2.06 a share, 17%. And on the midpoint of 2026 guidance, $690 million, today's price implies 4.1 times, against 4.3 times on the trailing figure.

What sits outside the enterprise value

Four items do not appear in the $2,856 million.

Roughly $260 million of tax assessments in Brazil, India and Mexico are carried with nothing accrued against them, about a fifth of market value, as set out in Consent Order and Claims. Herbalife had $150.8 million of issued but undrawn letters of credit and similar arrangements outstanding at 31 March 2026, of which roughly $110 million is the letter of credit and surety bonds posted against the Brazil assessments [34].

Share-based compensation was $44.1 million in 2025 [35], equal to 3.5% of market value and 17% of free cash flow, and it is added back in reaching Credit Agreement EBITDA [36]. With no open-market repurchases in 2023 through the first quarter of 2026 (Debt and Covenants), shares outstanding have risen from 100.2 million at the end of 2023 to 103,669,416 at 29 April 2026 [37].

The $277.5 million of convertible notes due June 2028 carry a conversion price of about $16.98 and are already inside the debt figure; principal is settled in cash and only value above the conversion price can be settled in shares [38]. Their effect is already visible in the share count: first-quarter 2026 diluted shares of 108.4 million against 103.8 million basic, with diluted earnings per share of $0.57 [39].

Finally, the earnings multiple most quotable from a screen is an adjusted one. Consensus of about $2.56 for 2026 puts the shares near 4.8 times forward earnings, but the company expects a full-year 2026 adjusted effective tax rate of approximately 30% [40] against the 17.2% realised in 2025, and reported 2026 earnings will also absorb a preliminary charge of approximately $95 million for the loss on extinguishment of the refinanced debt [41]. On enterprise value and cash flow the picture is steadier than the earnings line will look this year.

What would change the read

The evidence supports a specific read rather than a directional one: at $12.18 the equity is priced at roughly 4.6 times enterprise EBITDA and a 20% free-cash-flow yield, and almost all of the identifiable return from here is the transfer of about $593 million of net debt repayment across to the residual claim — $17.90 a share at an unchanged multiple. The strongest fact against it is that the identical transfer ran from 2021 to 2025 and the equity still lost 70%, because EBITDA and the multiple moved further than the debt did.

The report closes on three things that would move the read, each checkable in a filing:

Adjusted EBITDA holding the guided $675 million to $705 million range through the September 2026 anniversary of the India tax cut, which India Concentration shows is where the recent growth sits. Landing at the low end rather than the top of that range is about $1.25 a share at today's multiple, before any change in the multiple itself.

Net debt falling at the roughly $54 million a quarter the 2028 target requires, reported each quarter in the leverage reconciliation that Debt and Covenants works through. Free cash flow of $252.9 million in 2025 covers that and no more, so an acquisition of any size, or a working-capital reversal, competes directly with the target — as does the restored restricted-payments capacity set out in Pay and Capital Allocation.

And the multiple. At 3.0 times — between where Nu Skin and USANA trade — the equity is worth $2.57 to $4.02 a share on the same EBITDA. At 6.0 times, near where the retail names still sit, it is $20 to $23. That range is not a forecast; it is the width of the residual claim once the debt is fixed and only the multiple moves.